Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cetuximab + Ficlatuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 29||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Ficlatuzumab||AV-299|SCH900105||HGF Antibody 4||Ficlatuzumab (AV-299) is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885, PMID: 29346833, PMID: 32545260).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||head and neck cancer||not applicable||Cetuximab + Ficlatuzumab||Phase I||Actionable||In a Phase I trial, the combination of Erbitux (cetuximab) and Ficlatuzumab (AV-299) was tolerated and resulted in an overall response rate of 17% (2/12), a median progression-free survival (PFS) of 5.4 months, and an overall survival (OS) of 8.9 months in patients with advanced head and neck squamous cell carcinoma, baseline plasma scMet levels negatively correlated with PFS (HR = 1.92, p = 0.048), while tumor cMet or Hgf levels did not correlate with PFS or OS (PMID: 32545260; NCT02277197).||32545260|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03422536||Phase II||Ficlatuzumab Cetuximab + Ficlatuzumab||Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Recruiting|
|NCT02277197||Phase I||Cetuximab + Ficlatuzumab||Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)||Completed|